1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Belarus Pharmaceuticals and Healthcare Report Q1 2017

Belarus Pharmaceuticals and Healthcare Report Q1 2017

  • November 2016
  • -
  • Business Monitor International
  • -
  • 71 pages

Includes 3 FREE quarterly updates


>BMI View:
Government initiatives to reduce the reliance on pharmaceutical imports pose challenges for multinational drugmakers. The weak rouble has seen prices of foreign medicines rise to unaffordable levels and has led to state intervention in the form of domestic bias in the medicine tendering process, pricing controls and initiatives to boost the domestic drug-making industry. A poor economic outlook further deepens the risk to revenue earning opportunities.

Headline Expenditure Projections Pharmaceuticals: BYR12,247bn in 2015 (USD768mn) to BYR14,354bn (USD737mn) in 2016; +17.2% in local currency terms and -3.9% in US dollar terms. Forecast unchanged from last quarter. Healthcare: BYR47,932bn (USD3.00bn) in 2015 to BYR52,253bn (USD2.68bn) in 2016; +9.0% in local currency terms and -10.6% in US dollar terms. Forecast unchanged from last quarter. In BMI's Q117 Pharmaceutical Risk/Reward Index (RRI) Belarus is ranked 16th out of the 21 markets in the Central and Eastern European (CEE) matrix with an unchanged score of 46.6 compared with the previous quarter. Belarus scores considerably below the regional average score of 51.1 in Q117. Despite high sector value growth, the country's Rewards score is below the regional average on account of its low pharmaceutical expenditure. Belarus' total score is limited by its economic instability and unfavourable pharmaceutical regulatory environment.

Table Of Contents

Belarus Pharmaceuticals and Healthcare Report Q1 2017
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Belarus 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Belarus 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Belarus 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Belarus 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Belarus 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Belarus 2014-2020) 28
Industry Risk Reward Index 29
Central And Eastern Europe Risk/Reward Index - Q1 2017 29
Belarus Risk/Reward Index 35
Rewards 36
Risks 37
Regulatory Review 38
Intellectual Property Issues 39
Pricing And Reimbursement Regime 41
Market Overview 43
Healthcare Sector 44
Table: Healthcare Resources (Belarus 2010-2015) 46
Table: Healthcare Personnel (Belarus 2010-2015) 46
Table: Healthcare Activity (Belarus 2010-2015) 47
Research And Development 47
Clinical Trials 49
Epidemiology 49
Competitive Landscape 53
Research-Based Industry 53
Table: Multinational Market Activity 54
Generic Drugmakers 54
Pharmaceutical Distribution 56
Pharmaceutical Retail Sector 56
Company Profile 57
Lekpharm 57
Demographic Forecast 60
Demographic Outlook 60
Table: Population Headline Indicators (Belarus 1990-2025) 61
Table: Key Population Ratios (Belarus 1990-2025) 61
Table: Urban/Rural Population and Life Expectancy (Belarus 1990-2025) 62
Table: Population By Age Group (Belarus 1990-2025) 62
Table: Population By Age Group % (Belarus 1990-2025) 63
Glossary 65
Methodology 67
Pharmaceutical Expenditure Forecast Model 67
Healthcare Expenditure Forecast Model 67
Notes On Methodology 68
Risk/Reward Index Methodology 69
Index Overview 70
Table: Pharmaceutical Risk/Reward Index Indicators 70
Indicator Weightings 71

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.